HCW Biologics Inc

HCWB

Company Profile

  • Business description

    HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

  • Contact

    2929 N. Commerce Parkway
    MiramarFL33025
    USA

    T: +1 954 842-2024

    https://www.hcwbiologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    35

Stocks News & Analysis

stocks

Chip stock selloff deepens in Asia, extends to Europe and US

The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks

Downgrade for ASX listed fund manager as redemptions pile on

Persistent outflows erode earnings outlook.
stocks

Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?

Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,940.40100.001.13%
CAC 407,956.7022.000.28%
DAX 4025,622.61239.990.95%
Dow JONES (US)52,002.41175.28-0.34%
FTSE 10010,881.9041.550.38%
HKSE24,186.83124.110.52%
NASDAQ26,140.03572.99-2.14%
Nikkei 22565,324.29898.341.39%
NZX 50 Index13,753.7379.07-0.57%
S&P 5007,659.4484.62-1.09%
S&P/ASX 2008,806.7087.001.00%
SSE Composite Index3,716.288.810.24%

Market Movers